Trial reportDermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]2026
NivobotulinumtoxinA in the Treatment of Lateral Canthal Lines Alone and With Concurrent Treatment of Glabellar Lines.
Trial report in Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.], 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBotulinum neurotoxins in aesthetic medicine require reconstitution, which may cause administration errors.
objectiveTo evaluate liquid nivobotulinumtoxinA treatment of lateral canthal lines (LCL) and glabellar lines (GL). MATERIALS AND
methodsParticipants with moderate-to-severe LCL with/without moderate-to-severe GL were enrolled in 2 double-blind randomized clinical trials. Study 002 participants received nivobotulinumtoxinA 24 U or placebo for LCL treatment. Study 006 participants received nivobotulinumtoxinA 24 U (LCL), nivobotulinumtoxinA 44 U (LCL+GL), or placebo. Each study allowed up to 2 additional doses. The composite primary end point was the proportion of participants achieving ≥2-grade improvement on the Facial Wrinkle Scale (FWS) by investigator and participant assessment at maximum smile; the coprimary end point was investigator- and participant-assessed FWS "none or mild" rating.
resultsAt Day 30, significant responder rates versus placebo were observed for LCL in Study 002 (30.3% vs 2.6%, p < .001) and for LCL and LCL+GL in Study 006 (20.6% and 22.8% vs 0%, p < .001) for the composite end point. "None or mild" investigator/participant assessment of LCL (Study 002: 62.7%/56.5%; Study 006: 56.4%/43.6%) and LCL+GL (60.8%/47.3%) were significantly higher versus placebo ( p < .001). Headache was the most common adverse event.
conclusionLiquid nivobotulinumtoxinA was effective and well-tolerated for treating moderate-to-severe LCL with/without GL.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.